New Hormone Therapy for Metastatic Castration-sensitive Prostate Cancer
The FDA has approved darolutamide for metastatic castration-sensitive prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
Progress Against Cancer
The FDA has approved darolutamide for metastatic castration-sensitive prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
The FDA has approved retifanlimab-dlwr, both alone and in combination with chemotherapy, for certain patients with anal squamous cell...
The FDA has approved telisotuzumab vedotin-tllv for certain patients with non-small cell lung cancer. The U.S. Food and Drug...
The FDA has approved belzutifan for certain patients with pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA)...
The FDA has approved avutometinib and defactinib for certain patients with KRAS-mutated low-grade serous ovarian cancer. The U.S. Food...
The FDA has approved penpulimab-kcqx for certain patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has...
The FDA has approved nivolumab with ipilimumab as a first-line treatment for advanced liver cancer. The U.S. Food and...
The FDA has approved nivolumab with ipilimumab in certain patients with advanced colorectal cancer. The U.S. Food and Drug...
The FDA has approved the Immunotherapy durvalumab in combination with chemotherapy for certain patients with resectable bladder cancer. The...
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The...